ライフサイエンスコーパス: shivering

1 g, arteriovenous shunt vasoconstriction, and shivering.

2 cing the thresholds for vasoconstriction and shivering.

3 erimental cold exposure designed to minimize shivering.

4 e comfortable in the cold, and reported less shivering.

5 and clinical protocols on how to best treat shivering.

6 nverse relationship between BAT activity and shivering.

7 are arteriovenous shunt vasoconstriction and shivering.

8 can also produce heat metabolically without shivering.

9 Nine patients experienced mild episodic shivering.

10 widely expressed uncoupling protein UCP2, or shivering.

11 Shivering (152 [37%] vs 59 [15%]; RR 2.54, 95% CI 1.95-3

12 Shivering (229 [47%] vs 82 [17%]; RR 2.80, 95% CI 2.25-3

13 Shivering after anesthesia or in the critical care setti

14 Brown adipose tissue (BAT) functions in non-shivering and diet-induced thermogenesis via its capacit

15 iac arrest requires deep sedation to prevent shivering and discomfort.

16 Surface CW provides beneficial control of shivering and improves the metabolic profile during TTM.

17 ratory distress syndrome, but cooling causes shivering and increases metabolism.

18 ections resulted in short-lived increases in shivering and longer decreases in locomotor activity, as

19 e of thermoregulation was caused by impaired shivering and nonshivering thermogenesis, whereas thermo

20 sham controls and iBAT-ablated mice stopped shivering and resumed routine physical activity, indicat

21 ingestion at 52 degrees C rapidly decreased shivering and sensations of cold compared to 37 degrees

22 id ingestion at 22 and 7 degrees C increased shivering and sensations of coolness to similar levels,

23 n, fluid ingestion at 52 degrees C decreased shivering and the sensation of coolness, whereas fluid i

24 With LRG ingestion, compared to shivering and thermal sensations with ingestion at 37 de

25 t study, we characterize the modification of shivering and whole-body thermal sensation during cold s

26 delayed drug metabolism, prolonged recovery, shivering, and thermal discomfort.

27 Both vasoconstriction and shivering are associated with autonomic and hemodynamic

28 s scored on a scale of 0-3 using the Bedside Shivering Assessment Scale (BSAS).

29 s in puberty, either dystonic/dyskinetic or "shivering" attacks, triggered by stretching, motor initi

30 he time of IDC, 72% of patients had signs of shivering (BSAS >0).

31 irmed that the industrial sections; cutting, shivering/crusting, and stitching were the principal con

32 were decreases in body movements, including shivering, during NREM sleep; body temperature and heart

33 scuss complications of hypothermia including shivering, electrolyte abnormalities, hemodynamic change

34 , and brown adipose tissue temperatures; and shivering EMGs in anesthetized rats following central an

35 ) and clonidine (100 mug/kg, i.v.) inhibited shivering EMGs, BAT SNA, and BAT thermogenesis, effects

36 y control, and prevents vasoconstriction and shivering in blocked areas.

37 -blocking agents may be used to manage overt shivering in therapeutic hypothermia.

38 Although shivering is one alternative mechanism of thermogenesis

39 Shivering occurred more frequently in the Arctic Sun gro

40 n in a dose-dependent manner without causing shivering or altering physiological parameters.

41 use (p = 0.03), baseline moderate to severe shivering (p = 0.04), and lower serum magnesium levels (

42 The shivering response appeared to be delayed and much reduc

43 on four occasions, to induce a steady-state shivering response, at which point two aliquots of 1.5 m

44 mine whether visceral thermoreceptors modify shivering responses to cold stress.

45 nalysis using linear comparisons calculating shivering risk-reduction ratios.

46 misoprostol group more commonly experienced shivering (RR 1.91, 95% CI 1.65 to 2.21, p<0.001) and fe

47 Shivering severity during each phase was scored on a sca

48 thermogenesis is a key player in muscle non-shivering thermogenesis (NST) and can compensate for los

49 ults indicate a potent inhibition of BAT and shivering thermogenesis by alpha2-AR activation in the r

50 bition of rat brown adipose tissue (BAT) and shivering thermogenesis by alpha2-AR agonists.

51 in obesity, but the effect of impairing non-shivering thermogenesis in BAT on lipid storage in WAT r

52 protein-1 (UCP1), which mediate adaptive non-shivering thermogenesis in mammals.

53 nes on brown adipose tissue suggest that non-shivering thermogenesis is an arena for intragenomic con

54 Non-shivering thermogenesis is required for survival of rode

55 to an inhibition of brown adipose tissue and shivering thermogenesis that is mediated by neurons in t

56 nd acute cold tolerance (partly a measure of shivering thermogenesis) in s/s mice were modestly but s

57 the first day of cold, a time of intense non-shivering thermogenesis, AMPK activity remained at basal

58 s, re-routing fatty acids to BAT to fuel non-shivering thermogenesis.

59 apacity of brown adipose tissue and thus non-shivering thermogenesis.

60 ssue, and not in the acute activation of non-shivering thermogenesis.

61 rd pathway mediates not only sympathetic and shivering thermogenic responses but also metabolic and c

62 The shivering threshold is usually a full 1 degrees C below

63 travenous meperidine were used to reduce the shivering threshold.

64 , triggering of the ventilator and degree of shivering) to assess the degree of neuromuscular blockad

65 Shivering was common in the misoprostol group, and nause

66 AT thermogenesis and survive by compensatory shivering with consequent acute weight loss.